Virological and serological characterization of critically ill patient with COVID-19 in the UK: a special focus on variant detection
暂无分享,去创建一个
M. Shankar-Hari | P. Simmonds | D. Bonsall | D. Menon | A. Gordon | K. Rowan | T. Golubchik | L. Estcourt | D. Roberts | H. Harvala | J. Ratcliff | P. Mouncey | M. Fish | Aislinn Jennings | A. Lamikanra | N. Ciccone | Dung Nguyen | R. Ploeg | Emma Laing | Amy M Evans | F. Al-Beidh | Jennifer Rhynne | Sarah Williams | Pat Tsang | U. Leuscher | W. Slack | Sheba Ziyenge | Marta Olivera | A. Jennings | Amy M. Evans | S. Williams
[1] Naomi R. Waterlow,et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.
[2] Katie Harman,et al. Interpretation of COVID-19 case fatality risk measures in England , 2021, Journal of Epidemiology & Community Health.
[3] P. Dormitzer,et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.
[4] L. Morris,et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, bioRxiv.
[5] A. Iwasaki,et al. Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes , 2021, medRxiv.
[6] Christopher M. Horvat,et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 , 2021, medRxiv.
[7] F. Polack,et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.
[8] N. Loman,et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data , 2021, medRxiv.
[9] A. Tanuri,et al. Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil , 2020, Journal of Virology.
[10] D. A. Jackson,et al. Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity , 2020, Cell.
[11] D. Follmann,et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia , 2020, The New England journal of medicine.
[12] Y. Shao,et al. Association of SARS-CoV-2 genomic load trends with clinical status in COVID-19: A retrospective analysis from an academic hospital center in New York City , 2020, PloS one.
[13] Lisa E. Gralinski,et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo , 2020, Science.
[14] G. Rodger,et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.
[15] Vineet D. Menachery,et al. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility , 2020, Nature.
[16] Christopher M. Horvat,et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. , 2020, JAMA.
[17] M. Shankar-Hari,et al. Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials , 2020, Critical Care.
[18] Rachel J. Johnson,et al. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[19] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[20] Lowell Ling,et al. Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19 , 2020, Journal of Infection.
[21] Herman Goossens,et al. The Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP CAP) study: rationale and design , 2020 .
[22] Yan Peng,et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.
[23] Wenhong Zhang,et al. Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients , 2020, Journal of Infection.